Ask about this productRelated genes to: SLC16A8 antibody
- Gene:
- SLC16A8 NIH gene
- Name:
- solute carrier family 16 member 8
- Previous symbol:
- -
- Synonyms:
- MCT3, REMP
- Chromosome:
- 22q13.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-07-19
- Date modifiied:
- 2016-02-17
Related products to: SLC16A8 antibody
Related articles to: SLC16A8 antibody
- Colorectal cancer (CRC) is a common malignant tumor with high invasiveness and mortality. Folic acid metabolism-related genes (FAMGs) are critical for DNA synthesis and repair, but their roles in CRC initiation and progression remain unclear. - Source: PubMed
Publication date: 2026/07/08
Bai LuLiu Bo - Focal epilepsy is characterized by progressive cortical thinning, particularly within limbic structures; however, whether this atrophy reflects acquired seizure-induced damage or shared genetic predisposition remains unresolved. - Source: PubMed
Publication date: 2026/03/26
Zhang DingyuanZhang QianqianLi GuangmingYu LingtingMa YanlingHong XiaoliKui YujieCai ShanshanSun JianguangZhu Zechao - Homologous recombination repair deficiency (HRD) is a key biomarker for targeting breast cancer (BC) with PARP inhibitors (e.g., olaparib), but its detection usually requires a comprehensive genomic analysis. We explored whether metabolic signatures could indicate HRD status. We refined published lactate metabolism gene sets to develop an HRD-related lactate signature using least absolute shrinkage and selection operator (LASSO) regression. Using this signature, we stratifiedmore than1000 TCGA BC samples into high- and low-risk groups. We compared tumor immune-cell composition between groups using CIBERSORT and assessed associations with sensitivity to over 500 anticancer drugs using the GDSC2 and CTRP2 databases. A two-gene lactate metabolism signature (HPDL and SLC16A8) was constructed to stratify patients into high- and low-risk prognostic groups. The high-risk group had significantly worse overall survival. High-risk tumors presented immunosuppressive features (reduced CD8+ T cells and follicular helper T cells, and increased M2 macrophages) and higher lactate metabolism scores than low-risk tumors did. Drug response analysis revealed that the low-risk group was more sensitive to several targeted agents, notably Nutlin-3 (an MDM2–p53 pathway inhibitor). We established a novel lactate metabolism signature that is predictive of prognosis and HRD in patients withBC. This signature provides mechanistic insight into the link between tumor metabolism and DNA repair and may help guide targeted therapy selection (e.g., MDM2 inhibitors) forbreast cancer patients. - Source: PubMed
Publication date: 2026/02/09
Lin YejueJiang LingtingHu ShiyaoZhang YunLuo Ming - Colorectal cancer (CRC) ranks as the third most prevalent cancer globally, and hypoxia-induced metabolic reprogramming is considered a key driver of its malignant progression. We read with interest the article by Tian , which examines the role of solute carrier family 16 member 8 (SLC16A8) in regulating the tumor microenvironment. The study provides valuable evidence supporting the dual mechanisms by which SLC16A8 influences CRC pathogenesis and offers new directions for clinical research. This work demonstrates that activation of the HIF-1α/SLC16A8 axis under hypoxic conditions enhances glycolytic flux and lactate production. Additionally, SLC16A8 facilitates lactate transport, thereby inducing endothelial-mesenchymal transition-a finding that underscores its functional significance in shaping the tumor microenvironment. We believe the mechanistic insights presented in this study contribute meaningfully to the understanding of CRC biology. We would like to share our interpretations and hope to further discuss with the authors certain unexplored aspects and potential connections in this area. - Source: PubMed
Li Jing-YuanJi GuangDang Yan-Qi - Acute myeloid leukemia (AML) exhibits significant heterogeneity and aggressiveness. This study aimed to investigate T cell heterogeneity in the AML tumor microenvironment using single-cell RNA sequencing (scRNA-seq) and identify potential biomarkers for prognosis and precision therapy. - Source: PubMed
Publication date: 2025/11/24
Chen YongyuLiang BinHe RuilinZhang Zhongming